News
XOMA
25.48
+3.62%
0.89
Weekly Report: what happened at XOMA last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at XOMA last week (0401-0405)?
Weekly Report · 04/08 11:45
*News On Kinnate Biopharma Inc. (KNTE) Now Under XOMA
Dow Jones · 04/03 21:08
XOMA CORPORATION ANNOUNCES CLOSING OF TENDER OFFER
Reuters · 04/03 13:00
Press Release: XOMA Corporation Announces Closing of Tender Offer
XOMA Corporation Announces Closing of Tender Offer Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right. XOMA has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. Kinnate stockholders will receive a price per share of $2,5879 in cash plus one non-tradeable contingent value right.
Dow Jones · 04/03 13:00
Weekly Report: what happened at XOMA last week (0325-0329)?
Weekly Report · 04/01 11:42
Weekly Report: what happened at XOMA last week (0318-0322)?
Weekly Report · 03/25 11:45
Press Release: XOMA Declares Quarterly Preferred Stock Dividends
XOMA Corporation is a biotechnology royalty aggregator. The preferred dividends will be paid on or about April 15, 2024. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company has an extensive and growing portfolio of assets.
Dow Jones · 03/21 11:30
XOMA Declares Quarterly Preferred Stock Dividends
Barchart · 03/21 06:30
XOMA Corp Entered Into A Merger Agreement To Acquire Kinnate Biopharma For A Base Cash Price Per Share Of $2.3352 Per Share And An Additional Cash Amount Of Not More Than $0.2527 Per Share
XOMA Corporation has entered into a merger agreement to acquire Kinnate Biopharma Inc. The acquisition is expected to close in April 2024. XOMA has extended the Offer's expiration date to April 2, 2024. Kinnate stockholders will receive an additional cash amount of up to $0.2527 per share.
Benzinga · 03/19 20:15
*XOMA: Cash Amount That Kinnate Stockholders Will Receive in Offer Is $2.5879 Per Shr >XOMA
Dow Jones · 03/19 20:13
*XOMA to Pay Base Cash Price of $2.3352 Per Shr of Kinnate and Additional Cash Amount of Not More Than $0.2527 Per Shr, Plus One Non-Tradeable CVR
Dow Jones · 03/19 20:12
*XOMA to Acquire Kinnate Biopharma >XOMA KNTE
Dow Jones · 03/19 20:11
Press Release: XOMA Announces Calculation of -2-
Kinnate's stockholders and other investors can obtain the Amended Tender Offer Statement for free at the SEC's website. Copies of the documents filed with the SEC by Kinnate are available free of charge. Kinnate stockholders can also obtain free copies of the Offer materials.
Dow Jones · 03/19 20:05
Press Release: XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
XOMA Corporation anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to its royalty portfolio. XOMA has entered into a merger agreement to acquire Kinnate Biopharma Inc. The company has extended the expiration date for Kinnate's tender offer. The acquisition is expected to close in April 2024.
Dow Jones · 03/19 20:05
Weekly Report: what happened at XOMA last week (0311-0315)?
Weekly Report · 03/18 11:43
Analysts Conflicted on These Healthcare Names: Xoma (XOMA) and Lexicon Pharmaceuticals (LXRX)
TipRanks · 03/11 16:01
Weekly Report: what happened at XOMA last week (0304-0308)?
Weekly Report · 03/11 11:39
Xoma Corp. Is Worried About This – Should You Be Worried Too?
TipRanks · 03/09 06:01
XOMA Corporation files $200M mixed securities shelf
Seeking Alpha · 03/08 21:44
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about Xoma Corp Del through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).